Physician profile
Barbara Matos
NPI 1326766197
$2,546.47
in general payments reported to CMS, 2019-2025
15 companies · $1,941 in 2025
The $1,941 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $14.22 · 2024: $592 · 2025: $1,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,387 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.48 |
| Education | $158.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $621.02 | 2024-2025 | Sucraid, Sucraid |
| Abbvie INC. | $362.19 | 2024-2025 | |
| Madrigal Pharmaceuticals | $284.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $236.18 | 2024-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $182.48 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $175.70 | 2024-2025 | Sutab, Suflave |
| Ardelyx, INC. | $153.47 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $125.95 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.65 | 2024-2025 | Eohilia, Entyvio |
| Celltrion USA INC. | $73.98 | 2024-2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $69.78 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $65.74 | 2025 | Dupixent |
| Lilly USA, LLC | $41.90 | 2023-2025 | Omvoh, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.48 | 2025 | Xifaxan |
| Evoke Pharma, INC. | $21.35 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Matos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.